Drug Overview

Dacarbazine (also known as DTIC) is a classic chemotherapy drug used to treat certain cancers, especially melanoma and some types of lymphoma. Unlike newer “smart” targeted drugs or immunotherapies, dacarbazine works by directly damaging cancer cell DNA to stop the cells from growing and dividing. It has been used for many years and is still an important option in selected patients, usually as part of a chemotherapy regimen.

Dacarbazine is given through an intravenous (IV) infusion in the hospital or day‑care chemotherapy unit. Because it is a traditional chemotherapy agent, it can cause side effects such as nausea, low blood counts, and hair loss, so patients are closely monitored during treatment.

Generic Name: Dacarbazine (common abbreviation: DTIC).
US Brand Name: Dacarbazine is the standard generic name; it is typically not sold under a separate brand name in the United States.
Drug Class: Alkylating chemotherapy agent / DNA‑damaging drug.
Route of Administration: Intravenous (IV) infusion, usually given in cycles over several weeks or months.
FDA Approval Status: FDA‑approved as an oncology drug; used mainly for metastatic melanoma and certain types of Hodgkin and non‑Hodgkin lymphoma, often in combination with other chemotherapy agents.

What Is It and How Does It Work? (Mechanism of Action)

Dacarbazine is an older chemotherapy drug that belongs to the alkylating agent family. Instead of being a “smart” targeted therapy, it works more broadly by damaging the DNA inside cancer cells, which stops them from growing and dividing properly.

At the molecular level, dacarbazine is a prodrug, meaning that it is not fully active when given. After the drug is infused into the bloodstream, the liver converts it into an active metabolite called MTIC (methyl‑triazeno imidazole carboxamide). MTIC can then enter cells and transfer a methyl group to specific parts of DNA, especially at the O⁶ and N⁷ positions on guanine bases. This alkylation (methylation) distorts the DNA structure, interferes with DNA replication and RNA synthesis, and can lead to DNA double‑strand breaks and cell death.

Because dacarbazine and its active metabolite target not only cancer cells, they can also affect normal, fast‑growing tissues such as the bone marrow, digestive tract lining, and hair follicles. This is why dacarbazine can cause side effects like low blood counts, hair loss, and nausea. The drug is not “cell‑cycle specific,” which means it can damage cells at different stages of the division cycle, rather than acting only at one specific phase.

FDA-Approved Clinical Indications

Dacarbazine is FDA‑approved for use in several cancers, mainly in combination with other chemotherapy drugs. It is not typically used as a “targeted therapy” or “smart” drug, but rather as a standard chemotherapy agent in selected regimens.

Oncological uses (FDA‑approved)

Metastatic cutaneous melanoma: Dacarbazine is an approved treatment for advanced skin cancer that has spread to other parts of the body. It may be used alone or in combination with other agents, depending on the patient and local guidelines.
Hodgkin lymphoma: Dacarbazine is part of some chemotherapy regimens for Hodgkin lymphoma, such as ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine), which is commonly used in certain stages of the disease.
Some soft tissue sarcomas: Dacarbazine may be included in chemotherapy combinations for certain types of soft tissue sarcoma, usually as part of a multi‑drug regimen rather than as a single agent.

Non‑oncological uses (if any)

There are currently no FDA‑approved non‑cancer (non‑oncological) uses for dacarbazine. Its development, approval, and common clinical use are focused entirely on cancer treatment.

Dosage and Administration Protocols

Dacarbazine is given as an intravenous infusion, and the dose is usually calculated based on the patient’s body surface area (height and weight). Because it is a classic chemotherapy drug, the exact dose and schedule depend on the cancer type, the combination regimen, and the patient’s age and overall health.

Typical IV dosing and schedule (adults)

Feature	Description
Standard dose (single‑agent melanoma)	Around 200–250 mg/m² given as an IV infusion over 20–60 minutes, repeated every 3 weeks in some melanoma protocols.
Dose in ABVD for Hodgkin lymphoma	Around 120 mg/m² IV over 20–30 minutes every 2–4 weeks as part of the ABVD regimen; the exact dose and schedule may vary by protocol.
Frequency of administration	Usually once every 2–4 weeks, depending on the regimen and the patient’s response and side effects.
Route of administration	Intravenous (IV) infusion, typically mixed with fluids and given in a hospital or day‑care oncology unit.
Typical treatment duration	Continues for several cycles (e.g., 4–6 cycles or more), as long as the cancer responds and the patient tolerates treatment.

Dose adjustments for renal or hepatic insufficiency

There is no simple, universally agreed standard dose‑reduction rule for dacarbazine in patients with kidney or liver problems. Because the drug is activated and cleared by the liver, some oncology teams may reduce the dose in patients with moderate to severe liver impairment or adjust the treatment schedule. In patients with significant kidney disease, clinicians monitor blood counts and organ function closely and may adjust the dose based on toxicity and overall tolerance.

Patients should always follow the dosing and scheduling instructions given by their oncology team and should not change the dose without medical approval.

Clinical Efficacy and Research Results

Dacarbazine has been used for many years, and more recent studies from roughly 2020–2025 continue to describe its role in selected cancers, usually as part of combination therapy. Because targeted therapies and immunotherapies have become more common, dacarbazine is now often chosen for patients who cannot receive or tolerate these newer agents.

In metastatic melanoma, older and recent data show that dacarbazine as a single agent can produce tumor shrinkage in a subset of patients, but many responses are partial and not long‑lasting. Response rates are generally modest, with some studies reporting that about half of patients experience some tumor‑stabilizing or shrinking effect, while others do not respond. Median survival times in dacarbazine‑based programs vary widely, depending on cancer stage, prior treatments, and overall health.

Safety Profile and Side Effects

As a classic chemotherapy drug, dacarbazine has a broad side‑effect profile. It is not a “smart” targeted therapy or immunotherapy, so it can affect both cancer cells and normal tissues, especially those that divide rapidly. Patients are closely monitored before, during, and after each infusion.

Black Box Warning

There is currently no FDA‑specific Black Box Warning exclusively for dacarbazine alone, but classic chemotherapy drugs like dacarbazine carry important safety risks, including bone‑marrow suppression, fertility effects, and the possibility of secondary cancers after long‑term use. These are described in the drug’s prescribing information, and oncologists monitor patients accordingly.

Common side effects (>10%)

Nausea and vomiting, which can often be managed with modern anti‑nausea medicines.
Fatigue or feeling unusually tired.
Hair loss (alopecia), which usually grows back after treatment ends.
Low blood counts (anemia, low white blood cells, low platelets) increase the risk of infection, bruising, or bleeding.
Loss of appetite or mild taste changes.
Flu‑like symptoms such as mild fever, chills, or muscle aches.

Many of these effects are manageable with supportive care, dose adjustments, and close monitoring.

Serious adverse events

Severe bone‑marrow suppression, leading to very low white blood cell counts and a higher risk of life‑threatening infections.
Allergic or infusion‑related reactions during or shortly after the IV drip, including rash, shortness of breath, low blood pressure, or chest tightness.
Liver or kidney problems are seen as abnormal blood tests or symptoms such as jaundice, dark urine, or swelling.
Secondary cancers in the long term, especially after multiple chemotherapy regimens, although this risk is generally low in the short term.

Management strategies

For nausea and vomiting, patients are usually given anti‑nausea drugs before and after the infusion, along with clear instructions on hydration and diet.
If low blood counts are severe, treatment may be delayed or the dose reduced, and patients may receive growth‑factor support or antibiotics if an infection occurs.
Any signs of severe allergic reaction (rash, swelling, difficulty breathing, chest pain) should be treated as an emergency; the infusion should be stopped and emergency care initiated.
Regular blood tests, liver and kidney function tests, and clinical exams are performed before each cycle to detect serious problems early.

Connection to Stem Cell and Regenerative Medicine (If Applicable)

There is currently no strong evidence that dacarbazine is being used in combination with stem cell transplantation or regenerative medicine protocols in routine clinical practice. Its main role is as a standard chemotherapy agent in selected cancer regimens, rather than as a cell‑based or regenerative therapy.

However, because dacarbazine can suppress the bone marrow and damage rapidly dividing cells, it has sometimes been used in high‑dose therapy settings before stem cell or bone‑marrow transplantation, although this is not a standard indication everywhere. In such cases, the drug is used to weaken the patient’s own immune system or cancer‑bearing marrow so that transplanted stem cells can engraft and rebuild the blood system.

Patient Management and Practical Recommendations

Dacarbazine treatment requires careful planning, close monitoring, and good communication between patients and the oncology team.

Pre‑treatment tests to be performed

Blood tests: Complete blood count and white blood cell differential, liver and kidney function tests, and electrolytes to establish baseline health.
Imaging: CT scans, MRI, or PET scans to assess cancer stage and extent of disease.
Medical history: A detailed review of prior cancer treatments, allergies, other medical conditions, and current medications.

Precautions during treatment

Patients should attend all scheduled chemotherapy appointments and report any new or worsening symptoms, such as fever, severe fatigue, shortness of breath, bleeding, or unusual bruising.
They should avoid starting new medicines, including over‑the‑counter drugs or herbal supplements, without checking with the oncology team, as some can interact with chemotherapy.
Patients should practice good hygiene, avoid crowded places during periods of low blood counts, and seek urgent care if they develop a fever or signs of infection.

“Do’s and Don’ts” list

DO take all scheduled dacarbazine infusions as planned and follow the oncologist’s instructions about diet and fluids.
DO drink enough fluids and eat a balanced diet to support recovery between cycles.
DO attend all blood tests and clinic visits, and keep the oncology team informed of any side effects.
DO protect your skin from the sun, as chemotherapy can increase skin sensitivity.
DON’T skip doses or change the dose without talking to your oncologist.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice or a treatment recommendation. Dacarbazine is an FDA‑approved chemotherapy drug used for certain cancers, such as metastatic melanoma and selected lymphomas, usually as part of a combination regimen.